Mallet & Company: Federal Court Permanently Bans Bundy Baking Solutions from Selling Release Agent Products Derived from Stolen Mallet Trade Secrets

A federal judge permanently barred Bundy Baking and affiliate Synova from selling products derived from Mallet's trade secrets or with substantially similar formulas, and ordered destruction of related material. Mallet received audit rights for four years; Bundy must also provide seven days' notice before interviewing certain Mallet employees. The ruling follows a 2025 jury verdict finding willful and malicious trade-secret misappropriation; Bundy has appealed and has been ordered to pay more than $20 million in damages, fees, and costs.

Analysis

The economic upside to Vantage is conditional, not yet measurable: an enforceable exclusion could remove competing formulations and improve Mallet’s pricing or retention, but the order does not establish how much Bundy/Synova revenue is affected, whether customers can qualify substitutes quickly, or whether Mallet can capture displaced volume. In commercial baking, reformulation and line testing create switching friction; that may temporarily favor incumbents, while customers could instead dual-source or shift to other release-agent suppliers if supply or pricing becomes less attractive.

The key offset is execution and legal risk. Bundy/Synova’s appeal could narrow or stay relief, and the unusually broad four-year audit regime may generate disputes over product scope and compliance. Treat the plaintiff’s characterization and claimed remedy as one side’s account; verify the order, appeal status, any stay, and the specific products covered before assigning earnings value. The reported payment obligation is not enough to infer insolvency or operating disruption without balance-sheet and cash-flow data.

Near term, the order is more likely to move private-company bargaining power and customer qualification decisions than public-market earnings. Over 1–3 months, monitor appellate action and evidence of customer transfers; over 6–18 months, the durable effect depends on whether Bundy/Synova can redesign products without using protected information and whether customers accept alternatives. No mapped public ticker supports a clean direct trade. A thesis of Vantage share gains is falsified by a stay/reversal, narrow enforcement, or no evidence of customer wins; it is strengthened by upheld restrictions and verified account conversions.

Key Decisions for Investors

• No direct equity trade on this release alone: the supplied data contains no tickers, and the article provides no quantified exposure, affected sales, or public-market earnings bridge.
• Set an event watch on the appeal and any request for a stay. Reassess only after confirming the operative injunction, product scope, and whether the four-year audit provisions remain in force.
• For diligence on Vantage exposure, seek customer-level evidence of displaced Bundy/Synova volume, qualification timelines, pricing, and Mallet capacity. Do not capitalize presumed share gains before those data are available.
• Track competing release-agent suppliers and customer dual-sourcing behavior as potential beneficiaries if buyers avoid both parties; this is a watch item, not a named-stock recommendation absent verified supplier identities and exposure.